Abstract Background: According to the current recommendations, women with post-menopausal symptoms should be managed. Knowledge and perception of primary care physicians towards management of postmenopausal symptoms are deficient. Aim: The aim of the present study was to explore knowledge and attitude of primary care doctors towards management of postmenopausal symptoms. Methods: This study is a cross-sectional survey that was conducted from October to December 2010 in the five health regions in Kuwait. Two centers were selected randomly from each health region. All physicians who were currently working in the selected centers were asked to participate in the study. Out of 209 physicians, 142 agreed to participate and completed a self-administered questionnaire. Results: The study revealed that 82.4% of physicians had moderate knowledge about treatment options for postmenopausal symptoms, 88.0% discussed postmenopausal symptoms with their patients, and 45.1% of them either described or referred their patients for hormonal replacement therapy (HRT). The correct answers regarding 10 statements related to the Women Health Initiative finding were ranging from 2.8% to 78.9% which indicated low level of knowledge. Regarding the effectiveness of hormonal replacement therapy in postmenopausal women, the majority of the physicians agreed correctly that HRT is effective in prevention of osteoporosis (87.3%), treatment of vasomotor symptoms (83.7%), and treatment of vulvo-vaginal symptoms (82.4%). There was a variation among physicians opinion about the effectiveness of certain treatment options for managing hot flushes in postmenopausal women.
Introduction
Menopause is a physiological event occurring with ovarian failure and marks the end of women's reproductive life. 1 The average age of menopause is 51 years. 1 In 1960, the world population of women aged over 60 was below 250 million, but it is estimated that in the year 2030, 1,2 billion will be peri or postmenopausal and that this total will increase by 4.7 million a year. 2 The average woman in the developed world can now expect to spend approximately one-third of her life in postmenopausal state. 3 Because of these predicted changes in population structure, physicians are beginning to see that menopause is not a negligible phenomenon but a major public health problem. 2 Attitudes, perceptions, and expectations are part of the psychosocial phenomenon surrounding menopause. 4 Women in midlife and health professionals believe that attitude plays a role in the experience of menopause. 5 Hormonal changes at menopause are associated with numerous physical and psychological symptoms like vasomotor symptoms, sleep disturbances, mood alteration, depression, urinary tract infection, vaginal atrophy, and increased health risks for several chronic disorders including osteoporosis, cardiovascular disease, and loss of cognitive function. Menopausal symptoms are found to be less common in societies where menopause is viewed as a positive rather than negative event. 4 The Massachusetts women health study did a longitudinal study on more than 2000 women between 45 and 55 years. This study showed that negative attitude towards menopause leads to less favorable mode of climacteric. 6 This cultural aspect of menopausal symptoms has been discussed in a number of studies among Asian women including Japanese and Chinese population. 1 It is well established that hormonal replacement therapy (HRT) is an effective means of treating postmenopausal symptoms and preventing long term complications, such as osteoporosis. [7] [8] [9] [10] The HRT usage rate is low largely because majority remain poorly informed about this therapy. 11, 12 Therefore, doctor's knowledge and perception towards menopause and participation in health related activities is expected to be more in primary health care (PHC) centers. The present study was an approach to evaluate primary care physician's knowledge and attitude towards management of postmenopausal symptoms in primary health care centers in Kuwait.
Methods

Setting and design
The health care system in Kuwait is divided into five regional health authorities. PHC is provided by 82 centers served by either family practice physicians (FPs) or general practitioners (GPs). This study is a cross-sectional survey that was conducted from October to December 2010 in the five health regions. The sampling unit used in this survey was the health center. Ten centers were randomly selected from the official national list of all PHC (two from each health region). All PHC physicians who were currently working in the selected centers were asked to participate in the study. Out of 209 physicians, 142 physicians agreed to participate in the study and returned the filled self-administered questionnaires. Participation was optional and verbal consent was obtained prior to conducting the survey. All the necessary approvals for carrying out the research were obtained. The Ethical Committee of the Kuwaiti Ministry of Health approved the research.
Study questionnaires
The predesigned self-administered questionnaire derived from other published studies dealing with the same topic as well as from our own experience was used to collect the information from the physicians. The administrative time for filling it was 20-30 min. In order to maintain confidentiality, questionnaire was made anonymous. It consisted of two parts. The first part includes personal and working characteristics (age, gender, nationality, marital status, and years at work, specialty, education certificates and jobs). The second part included questions about knowledge and attitude of physicians towards menopause (having enough knowledge about treatment option for postmenopausal symptoms, discussion of postmenopausal symptoms with patients, prescription or referral of patient for HRT, absolute and relative contra indication for HRT in menopause).
Statistical analysis
The Statistical Package for Social Sciences (SPSS-17) was used for data processing. Simple descriptive statistics were used (mean ± standard deviation for quantitative variables, and frequency with percentage distribution for categorized variables).
Results
Out of 219 distributed questionnaires, 142 were returned back with 64.8% response rate. Table 1 describes the general characteristics of participating physicians. Their mean age ranged from 25 to 66 years was a mean of 43.3 ± 9.1 years, more than 80% of them were above 35 year of age. Males were predominating females (60.6% versus 39.4%). Most of physicians (81.7%) were non-Kuwaiti and 69.0% of them had 10 or more years of experience as PHC physicians. According to specialty, 78.2% were GPs and 21.8% were FPs. Nearly about two-third of the participating physicians have master, PhD or Board certificates (62.7%). Table 2 reveals that 6.3% of participating physicians said that they had poor knowledge about treatment options for postmenopausal symptoms and 82.4% declared that they had moderate knowledge. The majority of them (88.0%) stated that they have ever discussed postmenopausal symptoms with their patients. Among them, only 45.1% described or referred their patients for HRT.
Among those physicians who prescribed or referred patients for HRT, 50.0% did these for treatment of vasomotor symptoms, 37.5% attributed that for prevention or treatment of osteoporosis, while the minority did this for prevention of cardiovascular disease or treatment of cognitive symptoms (7.8% and 4.7%, respectively) Table 3 Illustrate the correct answers regarding 10 statements related to the Women Health Initiative finding. When the physician asked about the effect of prescribing estrogen plus progestin, only 12.7% answered correctly increased heart attack from multiple chooses. Only 2.8% chose correctly the increased risk of heart attack as a result of prescribing estrogen alone. According to FDA recommendations on hormonal therapy, 36.6% choose approved estrogen therapy for relief of moderate to severe hot flashes as correct choice. However, 31.0% of the physicians chose patients on combine HRT have increased risk of breast cancer after average 2-5 years correctly. Only 12.0% of the physicians chose correctly that FDA did not approved lower dose single tablet of prempro, containing 0.45 estrogen and 1.5 progestin for prevention of coronary heart disease or other cardiovascular disease. Severe liver disease, history of uterine fibrosis and venous thrombosis were chosen correctly as absolute contra indication for HRT in menopause by 78.9% of the physicians. On the other hand, only 21.8% chose correctly undiagnosed vaginal bleeding as relative contraindication for HRT in menopause. Regarding side effects, only 3.5% chose correctly severe abdominal pain as common side effect to HRT and 35.9% chose correctly severe depression as uncommon side effect to HRT. Moreover, 29.6% chose sexual desire is decreased after the menopause as correct answer.
Regarding physicians opinion about the effectiveness of HRT in postmenopausal women, the majority of the physicians agreed correctly that HRT is effective in prevention of osteoporosis (87.3%), treatment of vasomotor symptoms (hot flashes) (83.7%) and treatment of vulvo-vaginal symptoms (82.4%). On the other hand, around one-third of the physicians correctly disagreed that HRT is effective in prevention of chronic heart disease (28.1%), stroke (35.9%), treatment of dementia or Alzheimer (36.6%), skin wrinkles (33.1%), and increasing sexual Table 4 .
Discussion
Menopause induces a lot of disturbances in the body that the woman is most often not aware of. 13 Post-menopause is the stage in a woman's life that follows menopause. It is generally believed that the post-menopausal phase begins when 12 full months have passed since the last menstrual period. 1 It is accompanied by decreases of certain hormone production leading to a group of symptoms, bone loss, and the risk of heart disease. Although practice guidelines on HRT have been developed and several physician surveys and review articles have been published on the topic, there are few clear cut recommendations on when to prescribe HRT, which pretreatment investigations to conduct, which regimens to prescribe, how long HRT should be prescribed or what schedule of surveillance should be followed. [14] [15] [16] [17] [18] [19] [20] [21] In agreement with that, 82.4% of PHC physicians participating in this study declared that they had moderate knowledge about treatment options for postmenopausal symptoms. Moreover, although 88.0% of the physicians discussed postmenopausal symptoms with their patients, only about half of them either described or referred their patients for HRT. Our findings indicate that 50.0% of the physicians did these for treatment of vasomotor symptoms, 37.5% attributed that for prevention or treatment of osteoporosis, while the minority did this for prevention of CVD or treatment of cognitive symptoms (7.8% and 4.7%, respectively). These finding indicated that the vast majority of physicians are not familiar with the benefits of HRT described in the medical literature and practice guidelines (protection against osteoporosis, fractures and CAD) and risks from long-term use (endometrial and breast cancer).
Most agreement in the literature appears to be about the benefits of estrogen in preventing osteoporosis and fractures. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] There is some question about the benefits in preventing coronary artery disease (CAD). Observational studies suggested that the risk of CAD among estrogen users was about 30%-50% the risk among women not using estrogen. 17, 18 However, in a subsequent randomized controlled clinical trial involving women with CAD, the rate of CAD events was not reduced. 19 The majority of the respondents considered the prevention of osteoporosis and the presence of risk factors for osteoporosis as important or very important reasons for prescribing HRT. The results of the Women's Health Initiative (WHI) study of hormone therapy in post-menopausal women, published in 2002, have prompted many women and primary care physicians to reconsider the use of estrogen and progesterone hormone therapy to alleviate hot flashes. 20 In that study, 16,608 healthy, post-menopausal women with an intact uterus were randomized to receive therapy with conjugated equine estrogens plus medroxyprogesterone acetate, or placebo. 20 The results of the current study about the correct answers regarding 10 statements related to the Women Health Initiative finding revealed lower level of knowledge for all items except for the item related to absolute contra indication for HRT in menopause where, more than three quarters of physicians (78.9%) answered correctly severe liver disease, history of uterine fibrosis, venous thrombosis.
Doctors were not confident prescribing this type of therapy and considered it a specialized form of treatment that requires investigations. 13 Thus, most of the physicians surveyed were consistent with the epidemiological literature 18 and practice guidelines, 15, 16, 21 which recommend combined HRT for women who have an intact uterus and are at risk of endometrial cancer.
Although observational studies have consistently shown that estrogen protects against CAD, 17,18 a recent randomized, blinded, placebo-controlled trial involving menopausal women with CAD found that a combined estrogen-progestin regimen did not reduce the overall rate of CAD events. 19 Although that trial assessed HRT as secondary prevention, its findings will probably result in a re-evaluation of the role of estrogen in the prevention of heart disease. 22 Similarly, the majority of the participating physicians agreed correctly that HRT is effective in prevention of osteoporosis (87.3%), treatment of vasomotor symptoms (hot flashes) and treatment of vulvo-vaginal symptoms. On the other hand, a round one-third of the physicians correctly disagreed that HRT is effective in prevention of CHD, stroke, treatment of dementia or Alzheimer, skin wrinkles, and increasing sexual drive.
Regarding physicians' opinion about the effectiveness of certain treatment options for managing hot flashes in postmenopausal women, one-third of physicians in the present study agreed that SSRIs and venlafaxine (Effexor), a serotonin and norepinephrine reuptake inhibitor, as effective options for managing hot flashes in post-menopausal women. Other studies have shown an absolute risk reduction (ARR) in hot flashes of 19-60% with these agents compared with placebo. 23, 24 Clonidine (Catapres) has been found to reduce hot flashes by 12.7%. Similarly other studies reported a decrease by 15-20% (ARR) compared with placebo. 25, 26 Another study, in which clonidine was administered transdermally in 30 postmenopausal women, showed that clonidine decreased the number and the severity and duration of hot flashes compared with placebo. 26 PHC physicians have evaluated the effectiveness of soy isoflavones as tablets, capsules, and liquids in management of hot flashes in lower proportion (9.2%). A small pilot study of the effects of soy isoflavones in 39 menopausal women reported a 20% ARR in hot flashes weekly compared with placebo. 27 Other studies have shown no difference in effectiveness between isoflavones and placebo. 28, 29 The American College of Obstetricians and Gynecologists (ACOG) states that soy and isoflavones may be helpful in the short-term treatment of vasomotor symptoms. However, given the possibility of their interacting with estrogen, these agents should not be considered free of potential harm for women, particularly those who have an estrogen-dependent cancer. 30 Only 8.5% of the physicians reported the effectiveness red clover, like soy, contains isoflavones, which act as agonist/ antagonists on estrogenic receptors. In two small pilot studies, 31, 32 researchers compared red clover with placebo in postmenopausal women and found no difference in effectiveness of reducing hot flashes. In a randomized study with 252 menopausal women, researchers compared two different commercial red clover products with placebo. All groups reported significant declines in hot flashes compared with baseline, but neither of the red clover products demonstrated superiority over placebo. 33 Black cohosh shows promise for treatment of hot flashes, but study results are inconsistent. [34] [35] [36] Black cohosh is the most studied and perhaps the most popular herb for treatment of hot flashes. Typically, it is not used on a long-term basis. However, in the current study, black cohosh was reported as an effective management by 9.9% of the physician. A study in which 97 menopausal women were randomized to estrogen, black cohosh, or placebo showed black cohosh to be as effective as estrogen and superior to placebo in decreasing hot flash symptoms. 34 ACOG states that black cohosh may be helpful in the short-term treatment of women with vasomotor symptoms. 30 In consistent with other studies, other agents also have been used for the treatment of hot flash symptoms in menopause, including belladonna/ergotamine tartrate/phenobarbital combination, dong quai, evening primrose oil, gabapentin (neurontin), ginseng, mirtazapine (Remeron), trazodone (Desyrel), vitamin E, and wild yam, but there are few published data on their effectiveness. Belladonna/ergotamine tartrate/phenobarbital combination and gabapentin were more effective than placebo in reducing hot flashes in two small clinical trials. However, larger clinical studies are needed to support these initial findings. [37] [38] [39] [40] [41] [42] [43] [44] [45] 
Conclusion
The study revealed a general lack of knowledge about menopause and HRT. Better education about menopause and its management for healthcare providers in PHC is needed regarding the long-term risks associated with menopause and the role of HRT so that physician can take health decisions, which may results in improvement in quality of life of these women.
